Venture capitalist William Doyle has $ 35 million increase for a portfolio company with a promising, novel cancer therapy, as well as the global capital markets imploded in fall 2008. NovoCure, Ltd., an electric field treatment, as a cancer treatment fields, for the treatment of cancer tumors developed. The therapy has shown significant efficacy without side effects after five years of testing in human patients. Doyle believes NovoCure has the potential to be an important comp … Read more »

Venture capitalist William Doyle has $ 35 million increase for a portfolio company with a promising, novel cancer therapy, as well as the global capital markets imploded in fall 2008. NovoCure, Ltd., an electric field treatment, as a cancer treatment fields, for the treatment of cancer tumors developed. The therapy has shown significant efficacy without side effects after five years of testing in human patients. Doyle believes NovoCure has become a major new cancer therapy platform’s potential, a major company, but must complete clinical trials and obtain FDA approval central (phase III). Doyle venture capital firm WFD Ventures has invested $ 25 million to fund three rounds of pilot clinical trials for glioblastoma and other non-small cell lung cancer and the first pivotal clinical trial for glioblastoma. Additional funding is needed to go with the strategically important second registration trial. In the fall of 2008 Doyle was negotiating the final terms of an investment of two prominent hedge funds, when the liquidity crisis caused the hedge funds go out of business. Dole must now re-evaluate its options for securing the necessary funding for this promising young companies.
«Hide

from
William A. Sahlman,
Sarah Greene Flaherty
Source: Harvard Business School
31 pages.
Publication Date: Nov 24, 2009. Prod #: 810045-PDF-ENG
NovoCure Ltd. HBR case solution

[related_post themes="flat"]